BUPROPION HCL XL TABLET (EXTENDED-RELEASE)

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

BUPROPION HYDROCHLORIDE

제공처:

BAUSCH HEALTH, CANADA INC.

ATC 코드:

N06AX12

INN (국제 이름):

BUPROPION

복용량:

300MG

약제 형태:

TABLET (EXTENDED-RELEASE)

구성:

BUPROPION HYDROCHLORIDE 300MG

관리 경로:

ORAL

패키지 단위:

7/90

처방전 유형:

Prescription

치료 영역:

MISCELLANEOUS ANTIDEPRESSANTS

제품 요약:

Active ingredient group (AIG) number: 0131140004; AHFS:

승인 상태:

APPROVED

승인 날짜:

2021-09-16

제품 특성 요약

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
BUPROPION HCL
XL
Bupropion Hydrochloride Extended-Release Tablets
Tablet (extended-release), 150 mg, 300 mg, For oral use
USP
Antidepressant
Bausch Health, Canada Inc.
2150 St-Elzear Blvd. West
Laval, Quebec
H7L 4A8
Submission Control Number: 270781
Date
of Initial Authorization:
SEP 16, 2021
Date of Revision:
FEB 3, 2023
_ _
_Pr_
_BUPROPION HCL XL Product Monograph Page 2 of 59_
RECENT MAJOR LABEL CHANGES
3 SERIOUS WARNINGS AND PRECAUTIONS
01/2023
7 WARNING AND PRECAUTIONS
, Immune
01/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT
LISTED.
RECENT MAJOR LABEL
CHANGES……………………………………………………..…………2
TABLE OF CONTENTS
...........................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................... 4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
.............................................................................................................
4
1.2
Geriatrics…………………………………………………………………………………………………………….4
3
SERIOUS WARNINGS AND PRECAUTIONS
BOX………………………………………………………..…5
2
CONTRAINDICATIONS
................................................................................................
5
4
DOSAGE AND ADMINISTRATION
..............................................................................
5
4.1
Dosing Considerations
.........................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
..................................................... 5
4.4
Administration
............................................................................